---
type: claim
domain: health
description: "FDA's April 2025 roadmap aims to make animal studies 'the exception rather than the norm' within 3-5 years, endorsing AI-based models and organ-on-chip for preclinical testing — a structural shift that could address the 90% clinical failure rate by improving translatability"
confidence: experimental
source: "Bessemer Venture Partners, State of Health AI 2026 (bvp.com/atlas/state-of-health-ai-2026); FDA Strategic Roadmap April 2025"
created: 2026-03-07
sourced_from:
- inbox/archive/health/2026-01-01-bvp-state-of-health-ai-2026.md
supports:
- FDA Modernization Act 3.0
reweave_edges:
- FDA Modernization Act 3.0|supports|2026-04-26
---

# FDA is replacing animal testing with AI models and organ-on-chip as the default preclinical pathway which will compress drug development timelines and reduce the 90 percent clinical failure rate

In April 2025, the FDA announced a strategic roadmap to fundamentally restructure preclinical drug testing. The goal: make animal studies "the exception rather than the norm" within 3-5 years. The endorsed alternatives are AI-based predictive models, organ-on-chip systems, and in silico toxicity prediction.

This is not an incremental reform. The current preclinical paradigm — animal testing as the required gateway to human trials — has a catastrophic translatability problem: over 90% of drugs that appear safe and effective in animals fail in human efficacy or safety testing. The entire drug development pipeline (10-15 years, $1-2 billion per approved therapy) is built on a preclinical foundation that produces a 90%+ false positive rate.

Since [[AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics]], the current wave of AI drug discovery primarily accelerates the timeline without fixing the underlying translatability problem. AI can identify drug candidates faster, but if those candidates still go through animal models that don't predict human outcomes, the 90% failure rate persists.

The FDA's shift changes this equation. AI-based preclinical models trained on human biology data (not mouse biology extrapolated to humans) could improve translatability at the point where it matters most — before $100M+ is spent on clinical trials. Organ-on-chip systems use human tissue to test drug responses in physiologically relevant microenvironments. In silico toxicity prediction identifies safety signals from molecular structure rather than animal observation.

The economic context makes this urgent. Over 70% of Western preclinical work is currently offshored to China, creating both a strategic vulnerability and a quality concern. AI-native preclinical platforms would reshore this work while simultaneously improving it.

The confidence level is experimental because the roadmap is announced but not yet implemented. The 3-5 year timeline is aspirational. Regulatory inertia, pharma company conservatism, and the validation requirements for new preclinical approaches all create friction. But the direction is clear, and the economic pressure (90% failure rate at $1-2B per drug) creates strong incentive for adoption.

Since [[gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment]], the combination of AI-native preclinical testing and cheaper gene therapy delivery could simultaneously improve success rates and reduce costs — a compounding effect on the drug development pipeline.

---

Relevant Notes:
- [[AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics]] — the problem this FDA shift addresses
- [[gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment]] — parallel cost reduction in therapeutics delivery
- [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] — improved preclinical success rates could accelerate this curve
- [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — FDA demonstrating willingness for structural regulatory change

Topics:
- [[_map]]